Biocartis

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

30/12/2025

🚀 NOW AVAILABLE: 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐎𝐋𝐄-𝐏𝐎𝐋𝐃𝟏 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐀𝐬𝐬𝐚𝐲*
✅ Molecular classification of samples in ~ 95 min.
✅ Covers 99% of the known pathogenic & mutations
✅ Achieved 98.2% accuracy with 450+ endometrial cancer samples (Barault et al., 2024)
✅ Fit for use on small biopsies & directly from 1 FFPE tissue section
✅ No need for sample batching
✅ Straightforward results reporting

👉 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 https://www.biocartis.com/en/research/research-assays/idylla-pole-pold1-mutation-assay?utm_source=facebook&utm_medium=social&utm_campaign=3012_idylla-pole-pold1-mutation-assay

*For Research Use Only (RUO), not for use in diagnostic procedures.
Barault, L. et al. (2024). The Idylla™ POLE Mutation Assay, A New Tool For Direct Mutation Detection From FFPE Tissue. AMP 2024 Annual Meeting

26/12/2025

Revolutionize your CRC diagnostics with Idylla™ 🏆

⏱️Speed up your therapy decisions and alleviate patient anxiety*!

Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy.

Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, ensuring they receive the most effective treatment without delay.

👉 Read morehttps://biocartis.com/sites/default/files/2024-09/colorectal-leaflet-august2024.pdf

Your patients, our priority. Guiding them to the right therapy within hours ⚡

*Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.

24/12/2025

🌟In a season filled with lights, we’re proud to help 𝐛𝐫𝐢𝐧𝐠 𝐜𝐥𝐚𝐫𝐢𝐭𝐲 where it matters most – in patient care. With 𝐬𝐩𝐞𝐞𝐝, 𝐫𝐞𝐥𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲, 𝐚𝐧𝐝 𝐚𝐜𝐭𝐢𝐨𝐧𝐚𝐛𝐥𝐞 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬. Biocartis lights the way for clinicians to see the treatment path more clearly ✨
Happy Holidays from all of us at Biocartis! 🎄

22/12/2025

⏱️ Delayed or limited access to molecular testing results such as MSI/MMR can lead to 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐚𝐧𝐱𝐢𝐞𝐭𝐲, 𝐬𝐮𝐛𝐨𝐩𝐭𝐢𝐦𝐚𝐥 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐝𝐢𝐬𝐩𝐚𝐫𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬*.

💡 Real-world evidence has demonstrated that 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐌𝐒𝐈 is a 𝐛𝐞𝐭𝐭𝐞𝐫 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐦𝐞𝐭𝐡𝐨𝐝 than IHC to predict 𝐓𝐓𝐍𝐓, 𝐏𝐅𝐒 𝐚𝐧𝐝 𝐎𝐒 𝐰𝐢𝐭𝐡 𝐈𝐂𝐈**.

👉 The 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐂𝐃𝐱 𝐌𝐒𝐈 𝐓𝐞𝐬𝐭 is a fast testing solution that fits any hospital setting, helping overcome testing barriers, support equitable care and ensure optimal CRC patient outcomes.
𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞: https://www.biocartis.com/en-US/meet-idylla/idylla-oncology-assays/idylla-cdx-msi-test?utm_source=facebook&utm_medium=social&utm_campaign=2212_idylla-cdx-msi-test

Approved in the US under P250005.
* https://doi.org/10.1200/JCO.2025.43.16_suppl.3568; https://doi.org/10.1200/JCO.2024.42.3_suppl.29; https://doi.org/10.1097/01.COT.0000723664.21999.cc
** https://doi.org/10.1001/jamanetworkopen.2022.52244

19/12/2025

𝗥𝗘𝗩𝗜𝗦𝗜𝗧 𝗢𝗨𝗥 𝗙𝗥𝗘𝗘 𝗪𝗘𝗕𝗜𝗡𝗔𝗥: Translating new clinical insights into better outcomes: The role of biomarker testing in mCRC

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
- Treatment landscape of mCRC patients
- Key insights from the Checkmate-8HW clinical trial
- The Idylla™ CDx MSI Test and its fully automated workflow

👉 𝗪𝗮𝘁𝗰𝗵 𝗻𝗼𝘄: https://www.biocartis.com/en-US/publications/online-presentations/translating-new-clinical-insights-into-better-outcomes-the-role

𝙏𝙝𝙞𝙨 𝙬𝙚𝙗𝙞𝙣𝙖𝙧 𝙞𝙨 𝙞𝙣𝙩𝙚𝙣𝙙𝙚𝙙 𝙛𝙤𝙧 𝙐𝙎 𝙖𝙪𝙙𝙞𝙚𝙣𝙘𝙚𝙨 𝙤𝙣𝙡𝙮.
Idylla™ CDx MSI Test (A0220/6) is approved in the US under P250005.

17/12/2025

Molecular biomarker results in ONLY 3 HOURS!
💡 THINK IDYLLA™

Today, Biocartis offers tests supporting lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer.

More information 👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1112_meet-idylla

15/12/2025

🌟In a season filled with lights, we’re proud to help 𝐛𝐫𝐢𝐧𝐠 𝐜𝐥𝐚𝐫𝐢𝐭𝐲 where it matters most – in patient care. With 𝐬𝐩𝐞𝐞𝐝, 𝐫𝐞𝐥𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲, 𝐚𝐧𝐝 𝐚𝐜𝐭𝐢𝐨𝐧𝐚𝐛𝐥𝐞 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬, Biocartis lights the way for clinicians to see the treatment path more clearly ✨
Happy Holidays from all of us at Biocartis! 🎄

12/12/2025

📢 𝗡𝗢𝗪 𝗔𝗩𝗔𝗜𝗟𝗔𝗕𝗟𝗘: 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁
For the identification of MSI-H CRC patients who may benefit from treatment with 𝗢𝗣𝗗𝗜𝗩𝗢® (nivolumab) ± 𝗬𝗘𝗥𝗩𝗢𝗬® (ipilimumab)
✔️ 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗼𝗻 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 for standardized MSI-H and MSS detection in CRC
✔️ Sample to result in approximately 𝟭𝟱𝟬 𝗺𝗶𝗻𝘂𝘁𝗲𝘀 without the need for sample batching
✔️ Concordance rate of 𝟵𝟴.𝟱𝟳% against OncoMate™ MSI Dx Analysis System
✔️ Directly from 𝗙𝗙𝗣𝗘 𝘁𝗶𝘀𝘀𝘂𝗲, no paired tissue samples needed

👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://lnkd.in/e8r9Nhry

Approved in the US under P250005. OPDIVO® and YERVOY® are registered trademarks of Bristol Myers Squibb.

10/12/2025

💡𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿 𝗮 𝗳𝗮𝘀𝘁, 𝗰𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘄𝗮𝘆 𝘁𝗼 𝗱𝗲𝘁𝗲𝗰𝘁 𝗣𝗜𝗞𝟯𝗖𝗔 & 𝗔𝗞𝗧𝟭 𝗺𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀?

Discover the 𝗨𝗣𝗗𝗔𝗧𝗘𝗗 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗜𝗞𝟯𝗖𝗔-𝗔𝗞𝗧𝟭 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆:
✅ 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗰𝗼𝘃𝗲𝗿𝗮𝗴𝗲: Detection of 13 PIK3CA mutations and 1 AKT1 mutation
✅ 𝗠𝗶𝗻𝗶𝗺𝗮𝗹 𝘀𝗮𝗺𝗽𝗹𝗲 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀: Directly from 1 FFPE tissue section (5 - 10 µm) with hands-on time under 3 minutes
✅ 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄: Single-use cartridge, cost-effective, no batching required
✅ 𝗣𝗿𝗼𝘃𝗲𝗻 𝗮𝗰𝗰𝘂𝗿𝗮𝗰𝘆: 97% overall concordance versus NGS and real-time PCR tests*

👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en/research/research-assays/idylla-pik3ca-akt1-mutation-assay-0

For Research Use Only (RUO), not for use in diagnostic procedures.

09/12/2025

𝗝𝗢𝗜𝗡 𝗢𝗨𝗥 𝗙𝗥𝗘𝗘 𝗪𝗘𝗕𝗜𝗡𝗔𝗥: Translating new clinical insights into better outcomes: The role of biomarker testing in mCRC
📅 Thursday 11 December, 1:00 PM (EST)
🎤 Dr. Leon Pappas (Oncologist, Massachusetts General Hospital, USA) | Auditi DebRoy, PhD, MSc (Biomarkers & Diagnostics Global Medical Strategy Lead, Bristol Myers Squibb) | Christine Weyn, PhD, MSc (Senior Global Product Manager, Biocartis)
📍 Online, registration required

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
- Treatment landscape of mCRC patients
- Key insights from the Checkmate-8HW clinical trial
- The Idylla™ CDx MSI Test and its fully automated workflow

👉 𝗦𝗮𝘃𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗻𝗼𝘄: https://register.gotowebinar.com/register/5218303526885151835
Can’t join live? By registering, you will get access to the recording afterwards.

👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁: https://www.biocartis.com/en-US/meet-idylla/idylla-oncology-assays/idylla-cdx-msi-test

𝙏𝙝𝙞𝙨 𝙬𝙚𝙗𝙞𝙣𝙖𝙧 𝙞𝙨 𝙞𝙣𝙩𝙚𝙣𝙙𝙚𝙙 𝙛𝙤𝙧 𝙐𝙎 𝙖𝙪𝙙𝙞𝙚𝙣𝙘𝙚𝙨 𝙤𝙣𝙡𝙮.
Idylla™ CDx MSI Test (A0220/6) is approved in the US under P250005.

08/12/2025

💡 Early detection and prompt treatment are crucial for lung cancer patients
Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*.

IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️

Learn more 👉🏻https://www.biocartis.com/sites/default/files/2025-06/idylla_first-line_lung_1l_-_leaflet_-_may2025.pdf

*Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

05/12/2025

Join us at SIAPeC-IAP Congress 2025 in Milan, Italy 👋

Curious about getting your molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀 with Idylla™? ⏱️ Join Paulina and Dario at our booth - they’re ready to walk you through the specifics!

👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://www.biocartis.com/en/news-events/events/congresso-siapec-iap-2025
👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en/meet-idylla

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

http://www.biocartis.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.